The overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.was limited to relapsed/refractory grade 3B disease. Lisocabtagene maraleucel also carries relapsed/refractory B-cell lymphoma and lymphocytic leukemia indications.
The new approval was based on the phase 2 single-arm TRANSCEND FL trial in 94 patients with relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.Patients received a single dose 2-7 days after completing lymphodepleting chemotherapy.
The overall response rate was 95.7%. The median duration of response was not reached after a median follow-up of 16.8 months. The most common nonlaboratory adverse events, occurring in at least 20% of patients, were cytokine release syndrome, headache, musculoskeletal pain, fatigue, constipation, and fever.
Lisocabtagene maraleucel is available only through a Risk Evaluation and Mitigation Strategy program due to the risk for fatal cytokine release syndrome and neurologic toxicities.M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape Medical News. Alex is also an MIT Knight Science Journalism fellow.
Non-Hodgkin Lymphoma NHL Follicular Lymphoma Lymphoma Malignant Lymphoma B-Cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Timing Is Everything: CAR T for Follicular LymphomaCAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects.
Read more »
US State Dept broadens security vendor list amid Microsoft hacking woesUS State Dept broadens security vendor list amid Microsoft hacking woes
Read more »
Planned Parenthood broadens lawsuit, targeting mifepristone abortion restrictionsRelying on a new constitutional amendment, Planned Parenthood expands its suit against restrictive abortion laws.
Read more »
FDA receives patient reports of depression, suicide after taking weight loss drugsAn Atlanta man reported his suicide attempt to the FDA. Our investigators find he’s not the only one.
Read more »
In a first, FDA approves 3D-printed cranial implants to enter USFDA backs a first-of-its-kind cranial implant, which has been successfully used in 40 cranioplasties in Switzerland, Austria, and Israel.
Read more »
FDA winds down part of lead-contaminated applesauce probeBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »